The National Cancer Institute has made clinical trial participation a top national priority and yet participant levels are still not perhaps where they could be. Yes, this is a big decision for any patient/physician to make as far as whether or not to enroll, but many trials are offering lifesaving...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-02-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, My Commentaries, Investors, health insurance, Pharma, Cancer, clinical trials, HMO, Pharmaceuticals, R and D, Drug Development, Cancer Institute
This interview from Charlie Roses touches on many items and Nobel Prize Winner Muhammad Yunus adds what he has been able to accomplish in his part of the world in Bangladesh and how some of those principles can be applied here, coming together of both sides, different minds, different ideas that can...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-28-2008
Filed under:
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, healthcare, Biotech, Cancer, Pharmaceuticals, R and D, Economy, Banking, Milken Institute, Mahammed Yunus, Milken, Charlie Rose
This article brings up a good point, when a patient has no other choices and the potential of a new drug could offer some relief, what is the verdict at this point? The FDA has turned it's way of thinking around now to being much more conservative on the drugs that are approved. Do the drug companies...
The focus for the new facility will be cancer drugs and research. The hopes here are to provide a link between formulation and commercial manufacturing, in essence better availability to be created for patient accessibility related to clinical trials. BD ABBOTT PARK, Ill., June 12 -- Today...